MCK vs SYRE
McKesson Corporation vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
MCK
McKesson Corporation
57
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | MCK | SYRE |
|---|
| AI Score |
57
|
67
|
| Price |
$860.44
|
$106.50
|
| P/E Ratio |
22.89×
|
-54.61×
|
| ROE |
-219.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
3.6%
|
0.0%
|
| Debt / Equity |
-2.76×
|
0.00×
|
| Dividend Yield |
0.4%
|
0.0%
|
| RSI (14) |
50.5
|
57.1
|
| Beta |
0.307
|
3.026
|
| Expected Upside |
+4.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for MCK versus SYRE.
SYRE leads by 10 points.
SYRE scores 67/100 (Buy) versus MCK at 57/100 (Buy).
MCK Committee View
67% agreement
6 analysts
The primary driver is news sentiment is positive (+0.27 across 20 articles, 14d). The main limiting factor is current ratio of 0.85 is tight -- limited short-term liquidity cushion. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 39.4% shows genuine earnings power backing the valuation — Value
- EPS growing 49.1% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical